NASDAQ:MYL - Mylan Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$39.38 +0.05 (+0.13 %)
(As of 05/25/2018 04:00 PM ET)
Previous Close$39.38
Today's Range$39.19 - $39.89
52-Week Range$29.39 - $47.82
Volume2.09 million shs
Average Volume4.56 million shs
Market Capitalization$20.27 billion
P/E Ratio8.64
Dividend YieldN/A
Beta1.35

About Mylan (NASDAQ:MYL)

Mylan logoMylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, brand name, and over-the-counter (OTC) products worldwide. The company operates through three segments: North America, Europe, and Rest of World. It offers pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized, and cream or ointment forms. The company also manufactures and sells a portfolio of injectable products across various therapeutic areas, including respiratory and allergy, infectious disease, cardiovascular, oncology, and central nervous system and anesthesia; active pharmaceutical ingredients; anti-retroviral therapy products for people living with HIV/AIDS; and products in the therapeutic categories, such as hepatology, oncology, and critical care. In addition, it provides EpiPen Auto-Injector, which is used to treat severe allergic reactions; Perforomist Inhalation Solution, a formoterol fumarate inhalation solution for the maintenance treatment of bronchoconstriction in chronic obstructive pulmonary disorder patients; and Dymista, which is used for the treatment of seasonal allergic rhinitis. Further, it markets OTC products, including Cold-EEZE, Midnite, and Vivarin. The company markets its products to wholesalers, distributors, retail pharmacy chains, mail order pharmacies, group purchasing organizations, and government entities; and independent pharmacies, managed care organizations, hospitals, nursing homes, and pharmacy benefit managers. Mylan N.V. has collaboration and license agreements with Pfizer Inc., Momenta Pharmaceuticals, Inc., Theravance Biopharma, Inc., and Biocon Ltd. The company was formerly known as New Moon B.V. Mylan N.V. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

Receive MYL News and Ratings via Email

Sign-up to receive the latest news and ratings for MYL and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNASDAQ:MYL
CUSIP62853010
Phone44-0-17-0785-3000

Debt

Debt-to-Equity Ratio1.03
Current Ratio1.06
Quick Ratio0.65

Price-To-Earnings

Trailing P/E Ratio8.64
Forward P/E Ratio7.35
P/E Growth1.28

Sales & Book Value

Annual Sales$11.91 billion
Price / Sales1.70
Cash Flow$7.9395 per share
Price / Cash4.96
Book Value$25.56 per share
Price / Book1.54

Profitability

EPS (Most Recent Fiscal Year)$4.56
Net Income$696 million
Net Margins6.04%
Return on Equity18.56%
Return on Assets6.86%

Miscellaneous

Employees35,000
Outstanding Shares515,450,000

Mylan (NASDAQ:MYL) Frequently Asked Questions

What is Mylan's stock symbol?

Mylan trades on the NASDAQ under the ticker symbol "MYL."

How were Mylan's earnings last quarter?

Mylan (NASDAQ:MYL) posted its quarterly earnings results on Wednesday, May, 9th. The company reported $0.96 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.99 by $0.03. The business had revenue of $2.68 billion for the quarter, compared to the consensus estimate of $2.74 billion. Mylan had a return on equity of 18.56% and a net margin of 6.04%. Mylan's quarterly revenue was down 1.3% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.93 earnings per share. View Mylan's Earnings History.

When is Mylan's next earnings date?

Mylan is scheduled to release their next quarterly earnings announcement on Wednesday, August, 8th 2018. View Earnings Estimates for Mylan.

What guidance has Mylan issued on next quarter's earnings?

Mylan updated its FY18 earnings guidance on Wednesday, May, 9th. The company provided earnings per share (EPS) guidance of $5.20-5.60 for the period, compared to the Thomson Reuters consensus EPS estimate of $5.37. The company issued revenue guidance of $11.75-13.25 billion, compared to the consensus revenue estimate of $12.43 billion.

What price target have analysts set for MYL?

18 equities research analysts have issued 1-year price targets for Mylan's shares. Their predictions range from $29.39 to $59.00. On average, they anticipate Mylan's stock price to reach $47.0772 in the next twelve months. View Analyst Ratings for Mylan.

What are Wall Street analysts saying about Mylan stock?

Here are some recent quotes from research analysts about Mylan stock:
  • 1. Cantor Fitzgerald analysts commented, "Takeaways from the quarter: 1) The North America segment was down 8%, excluding Epipen, which declined $131.9MM in 4Q17, and $655.4MM in 2017. EU grew 16% in the quarter, and Rest of World grew 12%. 2) Generic drug pricing continued to be a headwind in the U.S. during the quarter. However, favorable pricing on existing products in Europe was a tailwind in 4Q17. 3) The Restasis target action date is in July 2018. The Biosimilar pegfilgrastim target action date is in early June. 4) MYL repurchased 12.4MM shares during 2017, and an additional 9.8MM shares in January 2018. 4) MYL expects to launch generic Adavir and Neulasta in 2018, and has risk-weighted these launches in its 2018 guidance." (3/1/2018)
  • 2. According to Zacks Investment Research, "Mylan received a major boost with the FDA approval for a generic version of Copaxone 40mg. The company being one of the first filers, will also enjoy 180 days of exclusivity. The FDA approval of biosimilar version of Herceptin will also boost the biosimilars portfolio. However, Mylan’s performance in 2017 was impacted by ongoing challenges in North America. The third quarter experienced an accelerated decline in EpiPen sales due to the launch of an authorized generic as well as the contraction of the overall epinephrine auto-injector market. Sales are expected to decline further. Moreover, the complete response letter from the FDA regarding its abbreviated new drug application ANDA for the generic version of asthma drug Advair Diskus was a setback given the market potential. Shares have performed better than the industry in the last one year." (1/16/2018)
  • 3. Argus analysts commented, "junior version" (8/22/2017)

Are investors shorting Mylan?

Mylan saw a drop in short interest during the month of April. As of April 30th, there was short interest totalling 18,066,577 shares, a drop of 8.3% from the April 13th total of 19,711,829 shares. Based on an average daily volume of 3,357,325 shares, the short-interest ratio is currently 5.4 days. Currently, 3.7% of the company's shares are sold short.

Who are some of Mylan's key competitors?

Who are Mylan's key executives?

Mylan's management team includes the folowing people:
  • Ms. Heather Bresch, CEO & Exec. Director (Age 49)
  • Mr. Rajiv Malik, Pres & Exec. Director (Age 57)
  • Mr. Kenneth S. Parks, Chief Financial Officer (Age 55)
  • Mr. Daniel M. Gallagher Jr., Chief Legal Officer (Age 45)
  • Mr. Anthony Mauro, Chief Commercial Officer (Age 45)

Has Mylan been receiving favorable news coverage?

News coverage about MYL stock has been trending somewhat positive this week, Accern Sentiment Analysis reports. Accern rates the sentiment of media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Mylan earned a daily sentiment score of 0.05 on Accern's scale. They also gave news coverage about the company an impact score of 47.17 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near term.

Who are Mylan's major shareholders?

Mylan's stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.75%), Pzena Investment Management LLC (4.14%), First Pacific Advisors LLC (1.84%), FIL Ltd (1.07%), Northern Trust Corp (1.06%) and Dimensional Fund Advisors LP (0.87%). Company insiders that own Mylan stock include Anthony Mauro, Heather M Bresch, Joseph C Md Maroon, Laboratories Abbott, Paul Campbell, Rajiv Malik and Robert J Coury. View Institutional Ownership Trends for Mylan.

Which institutional investors are selling Mylan stock?

MYL stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Point72 Asset Management L.P., Migdal Insurance & Financial Holdings Ltd., Clal Insurance Enterprises Holdings Ltd, Prudential Financial Inc., Pzena Investment Management LLC, BlackRock Inc. and State of Wisconsin Investment Board. Company insiders that have sold Mylan company stock in the last year include Anthony Mauro, Heather M Bresch, Paul Campbell, Rajiv Malik and Robert J Coury. View Insider Buying and Selling for Mylan.

Which institutional investors are buying Mylan stock?

MYL stock was purchased by a variety of institutional investors in the last quarter, including OppenheimerFunds Inc., Lord Abbett & CO. LLC, Korea Investment CORP, Neuberger Berman Group LLC, DekaBank Deutsche Girozentrale, Massachusetts Financial Services Co. MA, Redmile Group LLC and FIL Ltd. View Insider Buying and Selling for Mylan.

How do I buy shares of Mylan?

Shares of MYL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Mylan's stock price today?

One share of MYL stock can currently be purchased for approximately $39.38.

How big of a company is Mylan?

Mylan has a market capitalization of $20.27 billion and generates $11.91 billion in revenue each year. The company earns $696 million in net income (profit) each year or $4.56 on an earnings per share basis. Mylan employs 35,000 workers across the globe.

How can I contact Mylan?

Mylan's mailing address is BUILDING 4 TRIDENT PLACE MOSQUITO WAY, HATFIELD X0, AL10 9UL. The company can be reached via phone at 44-0-17-0785-3000 or via email at [email protected]


MarketBeat Community Rating for Mylan (MYL)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  595 (Vote Outperform)
Underperform Votes:  435 (Vote Underperform)
Total Votes:  1,030
MarketBeat's community ratings are surveys of what our community members think about Mylan and other stocks. Vote "Outperform" if you believe MYL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MYL will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Mylan (NASDAQ:MYL) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
18 Wall Street analysts have issued ratings and price targets for Mylan in the last 12 months. Their average twelve-month price target is $47.0772, suggesting that the stock has a possible upside of 19.55%. The high price target for MYL is $59.00 and the low price target for MYL is $29.39. There are currently 5 hold ratings and 13 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.722.742.632.61
Ratings Breakdown: 0 Sell Rating(s)
5 Hold Rating(s)
13 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
5 Hold Rating(s)
14 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
7 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
7 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $47.0772$47.2311$45.0732$41.2744
Price Target Upside: 19.55% upside16.02% upside8.22% upside10.39% upside

Mylan (NASDAQ:MYL) Consensus Price Target History

Price Target History for Mylan (NASDAQ:MYL)

Mylan (NASDAQ:MYL) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/23/2018JPMorgan Chase & Co.Set Price TargetBuy$53.00LowView Rating Details
5/9/2018Cantor FitzgeraldSet Price TargetHold$41.00LowView Rating Details
4/23/2018Wells Fargo & CoReiterated RatingHoldLowView Rating Details
4/12/2018Leerink SwannUpgradeMarket Perform ➝ Outperform$44.00LowView Rating Details
4/9/2018Morgan StanleySet Price TargetBuy$50.00HighView Rating Details
4/3/2018Royal Bank of CanadaSet Price TargetHold$45.00LowView Rating Details
3/15/2018MizuhoBoost Price TargetBuy$45.00 ➝ $51.00LowView Rating Details
3/1/2018UBSSet Price TargetBuy$54.00HighView Rating Details
1/25/2018Susquehanna BancsharesReiterated RatingPositive ➝ Positive$47.00 ➝ $55.00LowView Rating Details
1/24/2018Deutsche BankSet Price TargetBuy$50.00LowView Rating Details
1/11/2018Goldman Sachs GroupBoost Price TargetBuy$46.00 ➝ $52.00HighView Rating Details
1/4/2018CitigroupReiterated RatingBuy ➝ Buy$48.00 ➝ $58.00HighView Rating Details
12/12/2017GuggenheimInitiated CoverageBuy ➝ Buy$59.00LowView Rating Details
10/5/2017InstinetReiterated RatingBuy$37.00N/AView Rating Details
10/5/2017CowenReiterated RatingMarket Perform$30.00 ➝ $36.00N/AView Rating Details
10/4/2017BTIG ResearchBoost Price TargetBuy ➝ Buy$42.00 ➝ $45.00HighView Rating Details
9/29/2017BMO Capital MarketsReiterated RatingBuy$45.00LowView Rating Details
8/22/2017ArgusDowngradeBuy ➝ Hold$47.59 ➝ $29.39LowView Rating Details
5/22/2017BarclaysUpgradeEqual Weight ➝ Overweight$47.00 ➝ $50.00LowView Rating Details
12/30/2016Stifel NicolausReiterated RatingPositiveN/AView Rating Details
10/10/2016Raymond JamesUpgradeMarket Perform ➝ Strong-Buy$57.00N/AView Rating Details
9/23/2016Sanford C. BernsteinSet Price TargetBuy$60.00N/AView Rating Details
8/26/2016Evercore ISIReiterated RatingHold$49.00N/AView Rating Details
8/24/2016Bank of AmericaReiterated RatingBuy$70.00N/AView Rating Details
(Data available from 5/26/2016 forward)

Earnings

Mylan (NASDAQ:MYL) Earnings History and Estimates Chart

Earnings by Quarter for Mylan (NASDAQ:MYL)

Mylan (NASDAQ:MYL) Earnings Estimates

2018 EPS Consensus Estimate: $5.36
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181$0.92$0.92$0.92
Q2 20181$1.28$1.28$1.28
Q3 20181$1.43$1.43$1.43
Q4 20181$1.73$1.73$1.73

Mylan (NASDAQ MYL) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/7/2018$1.24N/AView Earnings Details
5/9/2018Q1 2018$0.99$0.96$2.7389 billion$2.6845 billionViewN/AView Earnings Details
2/28/2018Q4 2017$1.41$1.43$3.2910 billion$3.2390 billionViewListenView Earnings Details
11/6/2017Q3 2017$1.20$1.10$3.0927 billion$2.9871 billionViewN/AView Earnings Details
8/9/2017Q2 2017$1.18$1.10$2.9975 billion$2.9622 billionViewListenView Earnings Details
5/10/2017Q1 17$0.92$0.93$2.8130 billion$2.7195 billionViewN/AView Earnings Details
3/1/2017Q4 2016$1.42$1.57$3.1754 billion$3.2678 billionViewN/AView Earnings Details
11/9/2016Q3 2016$1.50$1.38$3.12 billion$3.06 billionViewListenView Earnings Details
8/9/2016Q216$1.13$1.16$2.58 billion$2.56 billionViewN/AView Earnings Details
5/3/2016Q116$0.74$0.76$2.23 billion$2.19 billionViewN/AView Earnings Details
2/10/2016Q415$1.27$1.22$2.71 billion$2.4907 billionViewListenView Earnings Details
10/30/2015Q315$1.38$1.43$2.79 billion$2.71 billionViewListenView Earnings Details
8/6/2015Q215$0.89$0.91$2.39 billion$2.37 millionViewN/AView Earnings Details
5/5/2015Q115$0.70$0.70$2.2220 billion$1.8717 billionViewListenView Earnings Details
3/2/2015Q414$1.05$1.05$2.07 billion$2.08 billionViewListenView Earnings Details
10/30/2014Q314$1.14$1.16$2.06 billion$2.08 billionViewN/AView Earnings Details
8/7/2014Q214$0.70$0.69$1.88 billion$1.84 billionViewN/AView Earnings Details
5/1/2014Q114$0.63$0.66$1.80 billion$1.72 billionViewN/AView Earnings Details
2/27/2014Q413$0.75$0.78$1.81 billion$1.81 billionViewN/AView Earnings Details
10/31/2013Q313$0.79$0.82$1.84 billion$1.77 billionViewN/AView Earnings Details
8/1/2013Q2 2013$0.67$0.68$1.73 billion$1.70 billionViewN/AView Earnings Details
5/2/2013Q1 2013$0.62$0.62$1.6939 billion$1.6315 billionViewN/AView Earnings Details
2/27/2013Q4 2012$0.64$0.65$1.73 billion$1.72 billionViewN/AView Earnings Details
10/25/2012$0.77$0.83ViewN/AView Earnings Details
7/26/2012$0.55$0.60ViewN/AView Earnings Details
4/26/2012$0.51$0.52ViewN/AView Earnings Details
2/21/2012$0.50$0.53ViewN/AView Earnings Details
10/26/2011$0.51$0.55ViewN/AView Earnings Details
7/27/2011$0.45$0.52ViewN/AView Earnings Details
5/3/2011$0.44$0.44ViewN/AView Earnings Details
2/24/2011$0.45$0.45ViewN/AView Earnings Details
10/26/2010Q3 2010$0.42$0.43ViewN/AView Earnings Details
7/28/2010Q2 2010$0.38$0.37ViewN/AView Earnings Details
4/29/2010Q1 2010$0.34$0.36ViewN/AView Earnings Details
2/25/2010Q4 2009$0.30$0.33ViewN/AView Earnings Details
10/29/2009Q3 2009$0.27$0.32ViewN/AView Earnings Details
7/30/2009Q2 2009$0.29$0.32ViewN/AView Earnings Details
4/30/2009Q1 2009$0.27$0.22ViewN/AView Earnings Details
2/19/2009Q4 2008$0.14$0.26ViewN/AView Earnings Details
10/30/2008Q3 2008$0.12$0.23ViewN/AView Earnings Details
8/6/2008Q2 2008$0.10$0.16ViewN/AView Earnings Details
5/8/2008Q1 2008$0.08$0.09ViewN/AView Earnings Details
2/27/2008Q4 2007($0.06)$0.11ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Mylan (NASDAQ:MYL) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Mylan (NASDAQ MYL) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.69%
Institutional Ownership Percentage: 83.66%
Insider Trading History for Mylan (NASDAQ:MYL)
Institutional Ownership by Quarter for Mylan (NASDAQ:MYL)

Mylan (NASDAQ MYL) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/6/2018Paul CampbellInsiderSell7,030$44.01$309,390.3017,054View SEC Filing  
3/6/2018Robert J. CouryDirectorSell50,000$43.41$2,170,500.00View SEC Filing  
3/2/2018Anthony MauroInsiderSell12,257$40.35$494,569.95147,435View SEC Filing  
3/2/2018Rajiv MalikPresidentSell50,000$40.91$2,045,500.00503,751View SEC Filing  
3/2/2018Robert J. CouryDirectorSell150,000$40.10$6,015,000.00View SEC Filing  
1/9/2018Heather M. BreschCEOSell75,000$45.00$3,375,000.00View SEC Filing  
6/9/2017Anthony MauroInsiderSell10,000$40.00$400,000.00140,653View SEC Filing  
6/9/2017Rajiv MalikPresidentSell25,000$40.00$1,000,000.00799,855View SEC Filing  
3/23/2017Laboratories AbbottMajor ShareholderSell44,000,000$41.60$1,830,400,000.00View SEC Filing  
8/9/2016Heather M BreschCEOSell100,200$50.00$5,010,000.00828,318View SEC Filing  
6/3/2016Joseph C Md MaroonDirectorBuy1,670$44.95$75,066.5022,036View SEC Filing  
5/25/2016Robert J CindrichDirectorBuy1,190$42.47$50,539.3013,384View SEC Filing  
5/12/2016Melina E HigginsDirectorBuy19,900$38.68$769,732.001,872View SEC Filing  
5/6/2016Melina E HigginsDirectorBuy100$38.69$3,869.001,872View SEC Filing  
4/28/2016Melina E HigginsDirectorBuy35,000$42.92$1,502,200.00View SEC Filing  
4/5/2016Robert J CouryChairmanSell217,755$45.96$10,008,019.801,334,306View SEC Filing  
3/31/2016Joseph C Md MaroonDirectorBuy4,337$46.36$201,063.3216,124View SEC Filing  
3/17/2016Mark W ParrishDirectorBuy1,705$44.00$75,020.0031,365View SEC Filing  
3/8/2016Wendy CameronDirectorBuy2,190$45.69$100,061.1066,677View SEC Filing  
3/3/2016Robert J CindrichDirectorBuy2,187$45.83$100,230.2110,322View SEC Filing  
12/17/2015John D. SheehanCFOSell34,579$55.03$1,902,882.37171,251View SEC Filing  
6/15/2015Melina E HigginsDirectorSell8,351$73.08$610,291.08View SEC Filing  
2/3/2015Anthony MauroInsiderSell13,255$53.15$704,503.25View SEC Filing  
2/3/2015Heather M BreschCEOSell411,996$53.15$21,897,587.40View SEC Filing  
2/3/2015Rajiv MalikPresidentSell285,394$53.15$15,168,691.10View SEC Filing  
2/3/2015Robert J CouryChairmanSell947,119$52.55$49,771,103.45View SEC Filing  
2/3/2015Rodney L PiattDirectorSell46,000$53.15$2,444,900.00View SEC Filing  
11/26/2014John D SheehanCFOSell19,475$57.50$1,119,812.50View SEC Filing  
11/25/2014Heather M BreschCEOSell100,000$55.80$5,580,000.00View SEC Filing  
11/25/2014Rajiv MalikPresidentSell120,000$55.78$6,693,600.00View SEC Filing  
11/25/2014Robert J CouryChairmanSell165,700$55.78$9,242,746.00View SEC Filing  
11/24/2014Heather M BreschCEOSell80,222$55.86$4,481,200.92View SEC Filing  
11/24/2014Rajiv MalikPresidentSell84,300$55.86$4,708,998.00View SEC Filing  
11/24/2014Robert J CouryChairmanSell105,800$55.88$5,912,104.00View SEC Filing  
11/7/2014Melina E HigginsDirectorBuy14,000$52.45$734,300.00View SEC Filing  
9/18/2014Neil F DimickDirectorSell5,432$48.26$262,148.32View SEC Filing  
6/19/2014Neil F DimickDirectorSell5,432$50.81$275,999.92View SEC Filing  
4/22/2014Rajiv MalikPresidentSell80,000$50.00$4,000,000.00289,117View SEC Filing  
4/14/2014Heather BreschCEOSell75,000$46.07$3,455,250.00293,418View SEC Filing  
3/20/2014Neil DimickDirectorSell5,813$53.08$308,554.0432,136View SEC Filing  
3/14/2014C ToddDirectorSell10,000$53.00$530,000.0023,389View SEC Filing  
3/6/2014Harry KormanCOOSell31,970$54.54$1,743,643.80133,373View SEC Filing  
3/3/2014Anthony MauroInsiderSell20,000$54.81$1,096,200.0025,473View SEC Filing  
3/3/2014Daniel Rizzo, Jr.CAOSell8,003$55.50$444,166.5082,296View SEC Filing  
3/3/2014Douglas LeechDirectorSell10,000$55.40$554,000.0036,271View SEC Filing  
1/2/2014Neil DimickDirectorSell5,813$43.15$250,830.9532,136View SEC Filing  
12/19/2013Rodney PiattDirectorSell10,000$41.84$418,400.0062,436View SEC Filing  
12/12/2013Daniel Rizzo, Jr.CAOSell70,683$42.04$2,971,513.3268,971View SEC Filing  
12/12/2013Melina HigginsDirectorBuy5,000$42.03$210,150.00View SEC Filing  
9/6/2013Heather M BreschCEOSell160,000$35.35$5,656,000.00View SEC Filing  
6/3/2013Neil F DimickDirectorSell19,994$30.51$610,016.94View SEC Filing  
11/27/2012Daniel C Rizzo JrCAOSell161,124$27.28$4,395,462.72View SEC Filing  
11/2/2012Douglas J LeechDirectorSell44,280$25.94$1,148,623.20View SEC Filing  
11/1/2012Anthony MauroInsiderSell12,301$25.79$317,242.79View SEC Filing  
10/5/2012Anthony MauroInsiderSell12,296$24.84$305,432.64View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Mylan (NASDAQ MYL) News Headlines

Source:
DateHeadline
Mylan (MYL) Given a $53.00 Price Target by JPMorgan Chase & Co. AnalystsMylan (MYL) Given a $53.00 Price Target by JPMorgan Chase & Co. Analysts
www.americanbankingnews.com - May 24 at 1:02 PM
Pfizer under pressure to resolve shortage of life-saving EpiPenPfizer under pressure to resolve shortage of life-saving EpiPen
www.ft.com - May 24 at 8:39 AM
Cantor Fitzgerald Weighs in on Mylans FY2018 Earnings (MYL)Cantor Fitzgerald Weighs in on Mylan's FY2018 Earnings (MYL)
www.americanbankingnews.com - May 24 at 8:35 AM
Wall Street Sees Upside of More than 17% for JNJ in the Next YearWall Street Sees Upside of More than 17% for JNJ in the Next Year
finance.yahoo.com - May 22 at 5:16 PM
Why Mylan NV.’s (NASDAQ:MYL) ROE Of 5.44% Does Not Tell The Whole StoryWhy Mylan NV.’s (NASDAQ:MYL) ROE Of 5.44% Does Not Tell The Whole Story
finance.yahoo.com - May 19 at 8:45 AM
Mylan (MYL) Expected to Post Quarterly Sales of $3.00 BillionMylan (MYL) Expected to Post Quarterly Sales of $3.00 Billion
www.americanbankingnews.com - May 19 at 3:02 AM
Mylan Target of Unusually High Options Trading (MYL)Mylan Target of Unusually High Options Trading (MYL)
www.americanbankingnews.com - May 18 at 6:46 AM
Mylan (MYL): Biocons Bangalore Facility Re-Inspections Likely Not Required, Observations Benign - GuggenheimMylan (MYL): Biocon's Bangalore Facility Re-Inspections Likely Not Required, Observations Benign - Guggenheim
www.streetinsider.com - May 17 at 5:15 PM
Zacks: Brokerages Anticipate Mylan (MYL) Will Announce Earnings of $1.23 Per ShareZacks: Brokerages Anticipate Mylan (MYL) Will Announce Earnings of $1.23 Per Share
www.americanbankingnews.com - May 17 at 1:14 PM
Teva Stock Up 5% as Buffett's Berkshire Raises Stake in Q1Teva Stock Up 5% as Buffett's Berkshire Raises Stake in Q1
finance.yahoo.com - May 16 at 5:22 PM
Mylan N.V. -- Moodys assigns Baa3 to Mylans Euro offeringMylan N.V. -- Moody's assigns Baa3 to Mylan's Euro offering
finance.yahoo.com - May 16 at 5:22 PM
Mylan (MYL) Upgraded to "Hold" at BidaskClubMylan (MYL) Upgraded to "Hold" at BidaskClub
www.americanbankingnews.com - May 16 at 10:30 AM
Mylan Inc. -- Moodys assigns Baa3 to Mylans Euro offeringMylan Inc. -- Moody's assigns Baa3 to Mylan's Euro offering
finance.yahoo.com - May 16 at 9:10 AM
Proctor & Gamble, Mylan And More Stocks Sending Strong Signals This WeekProctor & Gamble, Mylan And More Stocks Sending Strong Signals This Week
www.benzinga.com - May 14 at 5:14 PM
Mylan and West Virginia University Join Forces to Inspire West Virginia Youth Through STEM-CAREMylan and West Virginia University Join Forces to Inspire West Virginia Youth Through STEM-CARE
finance.yahoo.com - May 14 at 5:14 PM
Mylan Critic Blumenthal Asks FDA to Help End EpiPen ShortageMylan Critic Blumenthal Asks FDA to Help End EpiPen Shortage
finance.yahoo.com - May 14 at 5:14 PM
Mylan (MYL) Given Consensus Recommendation of "Buy" by AnalystsMylan (MYL) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - May 14 at 11:14 AM
Department of Justice seeks information from MylanDepartment of Justice seeks information from Mylan
finance.yahoo.com - May 14 at 9:57 AM
Mylan to Post Q2 2018 Earnings of $1.28 Per Share, Leerink Swann Forecasts (MYL)Mylan to Post Q2 2018 Earnings of $1.28 Per Share, Leerink Swann Forecasts (MYL)
www.americanbankingnews.com - May 14 at 2:02 AM
Mylan (MYL) Sees Large Decline in Short InterestMylan (MYL) Sees Large Decline in Short Interest
www.americanbankingnews.com - May 13 at 1:40 AM
Big pharma stocks unfazed by Trump speechBig pharma stocks unfazed by Trump speech
finance.yahoo.com - May 12 at 8:52 AM
Q3 2018 EPS Estimates for Mylan (MYL) Reduced by AnalystQ3 2018 EPS Estimates for Mylan (MYL) Reduced by Analyst
www.americanbankingnews.com - May 11 at 10:15 AM
BRIEF-Mylan Says Non-Contingent Payments For 4 Agreements Total About $265 MlnBRIEF-Mylan Says Non-Contingent Payments For 4 Agreements Total About $265 Mln
www.reuters.com - May 11 at 9:30 AM
DoJ investigates Mylan on trade compliance for certain productsDoJ investigates Mylan on trade compliance for certain products
www.reuters.com - May 11 at 9:30 AM
BMO Capital Reiterates Outperform on Mylan (MYL) Following Mixed 1QBMO Capital Reiterates Outperform on Mylan (MYL) Following Mixed 1Q
www.streetinsider.com - May 10 at 5:15 PM
Use an EpiPen? FDA notes some shortages of injector used to treat allergies, bug bitesUse an EpiPen? FDA notes some shortages of injector used to treat allergies, bug bites
www.usatoday.com - May 10 at 5:15 PM
Edited Transcript of MYL earnings conference call or presentation 9-May-18 2:00pm GMTEdited Transcript of MYL earnings conference call or presentation 9-May-18 2:00pm GMT
finance.yahoo.com - May 10 at 5:14 PM
Epipen shortage should be short term: MylanEpipen shortage should be short term: Mylan
www.cnbc.com - May 10 at 8:43 AM
Mylan (MYL) Posts Quarterly  Earnings Results, Hits EstimatesMylan (MYL) Posts Quarterly Earnings Results, Hits Estimates
www.americanbankingnews.com - May 9 at 6:14 PM
FDA adds Mylans EpiPen to shortage listFDA adds Mylan's EpiPen to shortage list
www.reuters.com - May 9 at 5:17 PM
BRIEF-Mylan Reports Q1 Adjusted Earnings Per Share Of $0.96BRIEF-Mylan Reports Q1 Adjusted Earnings Per Share Of $0.96
www.reuters.com - May 9 at 5:17 PM
Mylan First-Quarter Revenue Misses Estimate Amid Lower Sales of Branded ProductMylan First-Quarter Revenue Misses Estimate Amid Lower Sales of Branded Product
www.thestreet.com - May 9 at 5:17 PM
Mylan May Be Gem in Rough Generic SectorMylan May Be Gem in Rough Generic Sector
www.wsj.com - May 9 at 5:17 PM
FDA says Mylans EpiPen is in shortage in USFDA says Mylan's EpiPen is in shortage in US
www.reuters.com - May 9 at 5:17 PM
[$$] Mylan May Be Gem in Rough Generic Sector[$$] Mylan May Be Gem in Rough Generic Sector
finance.yahoo.com - May 9 at 5:17 PM
FDA says Mylans EpiPen is in shortage in U.S.FDA says Mylan's EpiPen is in shortage in U.S.
finance.yahoo.com - May 9 at 5:17 PM
FDA reports some EpiPen shortages due to manufacturing delaysFDA reports some EpiPen shortages due to manufacturing delays
finance.yahoo.com - May 9 at 5:17 PM
Mylan's 1st Quarter Results Are Weaker Than They Might SeemMylan's 1st Quarter Results Are Weaker Than They Might Seem
finance.yahoo.com - May 9 at 5:17 PM
Mylan (MYL) Q1 Earnings Lag on Weak North America SalesMylan (MYL) Q1 Earnings Lag on Weak North America Sales
finance.yahoo.com - May 9 at 5:17 PM
Mylan (MYL) Given a $41.00 Price Target at Cantor FitzgeraldMylan (MYL) Given a $41.00 Price Target at Cantor Fitzgerald
www.americanbankingnews.com - May 9 at 3:17 PM
Mylans 1st Quarter Results Are Weaker Than They Might SeemMylan's 1st Quarter Results Are Weaker Than They Might Seem
www.fool.com - May 9 at 2:52 PM
Mylan NV Stock Up Despite Q1 Earnings and Revenue MissMylan NV Stock Up Despite Q1 Earnings and Revenue Miss
investorplace.com - May 9 at 1:21 PM
Mylan (MYL) Updates FY18 Earnings GuidanceMylan (MYL) Updates FY18 Earnings Guidance
www.americanbankingnews.com - May 9 at 8:59 AM
Mylan Q1 non-GAAP EPS up 3%; reaffirms guidanceMylan Q1 non-GAAP EPS up 3%; reaffirms guidance
seekingalpha.com - May 9 at 8:38 AM
Mylans quarterly profit rises 31 percentMylan's quarterly profit rises 31 percent
www.nasdaq.com - May 9 at 8:38 AM
Mylan shares drop 2% after Q1 revenue missMylan shares drop 2% after Q1 revenue miss
www.marketwatch.com - May 9 at 8:38 AM
Mylan Reports First Quarter 2018 Results and Reaffirms 2018 GuidanceMylan Reports First Quarter 2018 Results and Reaffirms 2018 Guidance
www.prnewswire.com - May 9 at 8:38 AM
Reports of EpiPen shortage unfounded, Mylan saysReports of EpiPen shortage unfounded, Mylan says
www.cnn.com - May 9 at 8:38 AM
Will The U.S. Senate Candidates Cater To The Past Or Will West Virginias Coal Economy Evolve?Will The U.S. Senate Candidates Cater To The Past Or Will West Virginia's Coal Economy Evolve?
finance.yahoo.com - May 9 at 8:38 AM
Mylan misses revenue estimates as EpiPen sales dipMylan misses revenue estimates as EpiPen sales dip
finance.yahoo.com - May 9 at 8:38 AM

SEC Filings

Mylan (NASDAQ:MYL) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Mylan (NASDAQ:MYL) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Mylan (NASDAQ MYL) Stock Chart for Saturday, May, 26, 2018

Loading chart…

This page was last updated on 5/26/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.